Abstract
Daptomycin is licensed for the management of Staphylococcus aureus infections in adults, including those caused by meticillin-resistant S. aureus (MRSA). Few data exist on paediatric use or dose guidance in neonates. We report the case of a neonate with MRSA bacteraemia successfully managed with daptomycin. Dose requirements were substantially higher than those recommended for adults.
| Original language | English |
|---|---|
| Pages (from-to) | 381-383 |
| Number of pages | 3 |
| Journal | Journal of Medical Microbiology |
| Volume | 60 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2011 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Successful treatment of meticillin-resistant Staphylococcus aureus bacteraemia in a neonate using daptomycin'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver